[
  {
    "criterion": "Acknowledges irreducible uncertainty due to limited evidence on the use of topical cannabis-based preparations for pain management.",
    "points": 10,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Uses available systematic reviews as a reference framework to build the answer.",
    "points": 10,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Explains that there are still no robust, long-term clinical trials that conclusively demonstrate the efficacy and safety of cannabis-based topical preparations for neuropathic pain.",
    "points": 9,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Provides incorrect information about valid references. Xu DH et al. (2019) published a study on a topical formulation of CBD in patients with neuropathic pain, not a review. Eskander et al. (2020) reported two patients using a CBD cream for neuropathic and radicular pain, not a study with 29 patients.",
    "points": -8,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Mentions that the most commonly reported adverse effects are generally local, such as skin irritation, contact dermatitis, and pruritus, and warns that diabetic patients with sensitive skin or peripheral nerve damage may be more susceptible to adverse reactions.",
    "points": 7,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Mentions that with topical application, systemic absorption appears to be low but not zero, posing a risk of systemic side effects (e.g., sedation or dizziness), and it is still unknown if there is any risk of interaction with other medications.",
    "points": 8,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Suggests that if the therapy is chosen, only products whose quality, safety, and composition can be confirmed should be used.",
    "points": 7,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Mentions that data on long-term, chronic effects of topical cannabinoid use are still lacking.",
    "points": 7,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Advises informing the patient about the limitations of the evidence and the possibility of local side effects, and discussing realistic expectations regarding pain relief before starting the treatment.",
    "points": 8,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Misses to explain that cannabidiol, compared to THC, has shown stronger anti-inflammatory and analgesic properties when applied topically and has shown better results in neuropathic or musculoarticular pain, probably through actions on endocannabinoid system receptors and other receptors related to pain modulation. However, the quality of evidence is not strong enough due to multiple methodological limitations.",
    "points": -7,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Recommends that the treatment could be considered as an alternative therapy for neuropathic pain with close monitoring of efficacy and adverse effects, to be left to the discretion of the treating physician and in a joint decision-making setting with the patient.",
    "points": 6,
    "tags": [
      "level:example",
      "axis:completeness"
    ]
  }
]